Summary of Bicara Therapeutics Conference Call Company Overview - **Company**: Bicara Therapeutics (NasdaqGM:BCAX) - **Focus**: Development of ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-beta for treating HPV-negative head and neck squamous cell carcinoma (HNSCC) [2][4] Key Points and Arguments Clinical Development and Efficacy - **Ficerafusp alfa** is being studied in the pivotal **FORTIFY-HN01 trial** for first-line recurrent metastatic HPV-negative HNSCC [4][10] - Recent data presented at the **2026 Multidisciplinary Head and Neck Cancer Symposium** showed ficerafusp alfa has been administered to **90 patients**, demonstrating a well-tolerated safety profile and consistent efficacy [5][8] - The drug has shown a **2- to 3-fold improvement** in response rates, complete response rates, duration of response, and overall survival compared to standard care with pembrolizumab [8][9] - Current standard of care with pembrolizumab has a response rate of **19%** as a single agent and **36%** in combination with chemotherapy, with median overall survival of only **12-13 months** [8] Safety Profile - The combination of ficerafusp alfa and pembrolizumab has a manageable safety profile, with no new adverse events reported at the higher dose of **2,000 mg** every other week [14][15] - Common adverse events include EGFR-related events (e.g., rash) and mild TGF-beta-related events (e.g., epistaxis) [15] - One Grade 4 event of hypokalemia was reported, which resolved with standard treatment [15] Dosing Regimen - Bicara is exploring a **less frequent dosing regimen** for ficerafusp alfa, aiming to enhance patient convenience while maintaining efficacy [11][19] - The proposed regimen includes a **loading phase** followed by a **maintenance phase** every **3 weeks** [25][62] - Preliminary data supports that higher but less frequent dosing can sustain TGF-beta inhibition and lead to deeper clinical responses [20][22] Competitive Landscape - Bicara believes that ficerafusp alfa's differentiated efficacy will drive adoption, even with a weekly regimen [51] - The company aims to provide optionality for patients and clinicians by offering multiple dosing schedules [51][58] Future Plans - Bicara plans to seek **accelerated approval** for ficerafusp alfa with the **1,500 mg weekly regimen** while also conducting a parallel randomized study for the new loading and maintenance regimen [25][71] - The company is focused on optimizing dosing to match treatment needs as tumor burden decreases [24] Additional Important Insights - The data presented indicates that ficerafusp alfa can achieve deep tumor penetration and sustained responses, which are critical for long-term survival [17][26] - The company has built significant momentum in its clinical trials, with **111 sites** involved in the pivotal study [56] - Feedback from investigators highlights the differentiated safety profile of ficerafusp alfa compared to other EGFR inhibitors [57] This summary encapsulates the critical aspects of the conference call, focusing on the company's advancements, clinical data, safety profile, and strategic plans for ficerafusp alfa in treating HPV-negative head and neck cancer.